Observational studyJournal of neurology2018
Assessment of Duodopa
Observational study in Journal of neurology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Effects of Levodopa-Carbidopa Intestinal Gel on Dyskinesia and Non-Motor Symptoms Including Sleep: Results from a Meta-Analysis with 24-Month Follow-Up.Journal of Parkinson's disease · 2022Pooled it
- Intrajejunal Infusion of Levodopa/Carbidopa for Advanced Parkinson's Disease: A Systematic Review.Movement disorders : official journal of the Movement Disorder Society · 2021Pooled it
- Translating Evidence to Advanced Parkinson's Disease Patients: A Systematic Review and Meta-Analysis.Movement disorders : official journal of the Movement Disorder Society · 2021Pooled it
- The Effect of Dopaminergic Therapies in Parkinson's Disease on Non-Motor Symptoms.International journal of molecular sciences · 2025Review
- Improving Parkinson's disease management through wearable technology: A cost-benefit perspective.PloS one · 2025Article
- Direct Initiation of Levodopa-Carbidopa Intestinal Gel Infusion After a Positive Levodopa Challenge Test in Advanced Parkinson's Disease.Brain and behavior · 2024Article
- Caregiver Burden in Parkinson Disease: A Scoping Review of the Literature from 2017-2022.Journal of geriatric psychiatry and neurology · 2024Article
- Levodopa-Entacapone-Carbidopa Intestinal Gel Treatment in Advanced Parkinson's Disease: A Single-Center Study of 30 Patients.Movement disorders clinical practice · 2024Article
- Should continuous dopaminergic stimulation be a standard of care in advanced Parkinson's disease?Journal of neural transmission (Vienna, Austria : 1996) · 2023Review
- Pharmacological and Non-Pharmacological Treatments for Depression in Parkinson's Disease: An Updated Review.Medicina (Kaunas, Lithuania) · 2023Review
- Impact of advanced Parkinson's disease on caregivers: an international real-world study.Journal of neurology · 2023Article
- Levodopa Carbidopa Intestinal Gel in Advanced Parkinson's Disease: DUOGLOBE Final 3-Year Results.Journal of Parkinson's disease · 2023Observational
- Depression in Patients with Parkinson's Disease: Current Understanding of its Neurobiology and Implications for Treatment.Drugs & aging · 2022Review
- Single-Center Study of 103 Consecutive Parkinson's Disease Patients with Levodopa-Carbidopa Intestinal Gel.Movement disorders clinical practice · 2022Article
- Patient and caregiver outcomes with levodopa-carbidopa intestinal gel in advanced Parkinson's disease.NPJ Parkinson's disease · 2021Article
- DUOGLOBE: One-Year Outcomes in a Real-World Study of Levodopa Carbidopa Intestinal Gel for Parkinson's Disease.Movement disorders clinical practice · 2021Article
- Development of Quality of Life Questionnaire for Patients with Parkinson's Disease Undergoing STN-DBS.Neurologia medico-chirurgica · 2021Article
- Treatment Options for Motor and Non-Motor Symptoms of Parkinson's Disease.Biomolecules · 2021Review
- The Relationship Between Anxiety Disorders and Parkinson's Disease: Clinical and Therapeutic Issues.Current psychiatry reports · 2021Review
- Anxiety, depression, and quality of life in Parkinson's disease: the implications of multidisciplinary treatment.Neural regeneration research · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The gold standard of treatment in Parkinson's disease (PD) is levodopa/carbidopa whose long-term use induces motor and non-motor fluctuations and dyskinesias. Continuous infusion of intrajejunal levodopa/carbidopa intestinal gel (Duodopa
Indexed as
Identifiers
29951701What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.